EcoDrugPlus

Chemokine (C-X-C Motif) Receptor 4a

Ensembl ID : ENSGACG00000007282
Gene Symbol: CXCR4A
1 Cross references
216 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSGACG00000019294
Gene Symbol: CCKAR
2 Cross references
201 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSGACG00000003588
Gene Symbol: CCKBR
2 Cross references
195 Possible Orthologues:

Cholecystokinin B Receptor A

Ensembl ID : ENSGACG00000014143
Gene Symbol: CCKBRA
2 Cross references
198 Possible Orthologues:

Cholesteryl Ester Transfer Protein, Plasma

Ensembl ID : ENSGACG00000002410
Gene Symbol: CETP
1 Cross references
151 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSGACG00000010124
Gene Symbol: CHRM3
1 Cross references
188 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSGACG00000015318
Gene Symbol: CHRM3
1 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSGACG00000015349
Gene Symbol: CHRM4
1 Cross references
186 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSGACG00000016559
Gene Symbol: CHRNA3
1 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSGACG00000012100
Gene Symbol: CHRNB2
1 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSGACG00000016557
Gene Symbol: CHRNB4
1 Cross references
194 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSGACG00000019948
Gene Symbol: CHRM2A
1 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).